Obtenez 3 mois à 0,99 $/mois + 20 $ de crédit Audible

OFFRE D'UNE DURÉE LIMITÉE
Page de couverture de Unlocking the EU Market: Why Pure Global Advocates for an Authorized Representative with Physical Presence in Germany for MDR/IVDR Success.

Unlocking the EU Market: Why Pure Global Advocates for an Authorized Representative with Physical Presence in Germany for MDR/IVDR Success.

Unlocking the EU Market: Why Pure Global Advocates for an Authorized Representative with Physical Presence in Germany for MDR/IVDR Success.

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

 This episode of MedTech Global Insights delves into the critical role of the EU Authorized Representative (AR) under the stringent MDR and IVDR. We explore why the AR is no longer a passive administrative contact but a legally liable partner crucial for your market success. Choosing the right AR is a strategic decision that directly impacts your compliance, risk management, and ability to remain on the European market. We uncover the significant dangers of partnering with 'mailbox' AR services and highlight the non-negotiable value of an AR with a physical EU office, published regulatory capabilities, and a deep understanding of the new regulations. Learn how to identify a true regulatory partner who can protect your business, versus a simple address that could jeopardize your entire European operation. Case Study Highlight: Imagine your innovative medical device is gaining traction in Europe, but a critical compliance inquiry from a national authority goes unanswered by your 'virtual' AR. Suddenly, your market access is frozen, and you're facing a regulatory crisis from thousands of miles away. This episode explores how to avoid this costly and damaging pitfall. Key Takeaways: 1. Why is your EU Authorized Representative now legally liable for your products? 2. What are the hidden dangers of choosing a low-cost, 'mailbox only' AR service? 3. How can you verify if an AR truly has published MDR and IVDR capabilities? 4. Why does a physical office in an EU member state matter for regulatory interactions? 5. What specific questions must you ask a potential AR before signing a contract? 6. How does the AR's role integrate with your post-market surveillance and vigilance reporting? 7. What happens when a national competent authority tries to contact an unresponsive AR? 8. How can a single, qualified AR partner streamline access and ensure compliance across the entire EU market? For more information on navigating global MedTech regulations, contact us at info@pureglobal.com or visit https://pureglobal.com/.
Pas encore de commentaire